Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Galolay NT
- Development stage
- Unknown
- Lead developer
- Lloyd Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Galolay NT is a fixed-dose combination pharmaceutical product marketed by Lloyd Healthcare, primarily used for the management of neuropathic pain, including diabetic peripheral neuropathy. It contains two active ingredients: gabapentin and nortriptyline. Gabapentin is a gabapentinoid that acts as a ligand for the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, thereby reducing the release of excitatory neurotransmitters. Nortriptyline is a tricyclic antidepressant (TCA) that inhibits the reuptake of norepinephrine and, to a lesser extent, serotonin, which enhances descending inhibitory pain pathways. The combination is designed to provide synergistic relief for chronic nerve-related pain conditions often associated with diabetes.
- Brand names
- Galolay NT
- Other names
- Gabapentin and Nortriptyline Hydrochloride Tablets
02
Targets
SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)
Beyond the preview
Go deeper on Galolay NT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Galolay NT.